Vitamin D and prostate cancer

Proceedings of the Society for Experimental Biology and Medicine

Volumn 221, Issue 2, 1999, Pages 89-98

  Blutt, Sarah E ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; LEXACALCITOL; SEOCALCITOL; VITAMIN D; VITAMIN D RECEPTOR;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HYPERCALCEMIA; NONHUMAN; PROSTATE CANCER; VITAMIN D DEFICIENCY;

EID: 0032969561     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-60.x     Document Type: Conference Paper

References (143)

1. Doll R, Peto R. The causes of cancer. J Natl Cancer Inst 66:1191-1308, 1991.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10:1307-1312, 1990.
3. Haussler MR, Mangelsdorf DJ, Komm BS. Molecular biology of the vitamin D hormone. In: Clark JH, Ed. Recent Progress in Hormone Research: Proceedings of the 1988 Laurentian Hormone Conference. New York: Academic Press, Inc., pp263-305, 1988.
4. Anderson JJB, Toverud SU. Diet and vitamin D: A review with an emphasis on human function. J Nutr Biochem 5:58-65, 1994.
5. 3 in man. In: Kumar R, Ed. Vitamin D: Basic and Clinical Aspects. Boston: Martinus Nijhoff, pp197-216, 1984.
6. 3 on proliferation of cancer cells in vitro. Cancer Lett 120:65-69, 1997.
7. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG. Vitamin D receptors and antiproliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76:1017-1020, 1997.
8. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1:188-191, 1989.
9. 3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083-1086, 1981.
10. Feldman D, Showronski RJ, Peehl DM. Vitamin D and prostate cancer. In: American Institute of Cancer Research, Ed. Diet and Cancer. New York: Plenum Press, pp53-63, 1995.
11. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869, 1992.
12. Wu LY, Semenya KA, Hardy RE, Hargreaves MK, Robinson SB, Pederson L, Sung JF, Haynes MA. Cancer rate differentials between blacks and whites in three metropolitan areas: A 10-year comparison. J Natl Med Assoc 90:410-416, 1998.
13. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43-68, 1968.
14. Giovannucci E. How is individual risk for prostate cancer assessed? Hematol Oncol Clin North Am 10:537-548, 1996.
15. Zaridze DG. Cancer of the prostate: Epidemiology and aetiology. Br J Urol 59:493-502, 1987.
16. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16:187-197, 1990.
17. Lian JB, Stein GS. Transcriptional control of vitamin D-regulated proteins. J Cell Biochem 49:37-45, 1992.
18. Haussler MR, Jurutka PW, Hsieh J-C, Thompson PD, Selznick SH, Haussler CA, Whitfield GK. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Bone 17:33S-38S, 1995.
19. 3. Cancer Res 52:515-520, 1992.
20. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.
21. Newmark HL. Vitamin D adequacy: A possible relationship to breast cancer. Adv Exp Med Biol 364:109-114, 1994.
22. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med 19:614-622, 1990.
23. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993.
24. Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst 90:461-463, 1998.
25. 3 receptor in human breast cancer. Cancer Res 41:5121-5124, 1981.
26. 3 inhibitory effect on the growth of two human breast cancer cell lines. J Steroid Biochem 24:373-376, 1986.
27. 3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 191:221-226, 1989.
28. 3 receptor in bone, lung, and other cancers. Mol Carcinog 19:254-257, 1997.
29. 3 in human malignant melanoma cell lines. J Surg Res 61:127-133, 1996.
30. 3 and its fluorinated analogues. Cancer Res 44:5624-5628, 1984.
31. Studzinski GP, Moore DC. Sunlight: Can it prevent as well as cause cancer? Cancer Res 55:4014-4022, 1995.
32. Lawson DE, Paul AA, Black AE, Cole TJ, Mandal AR, Davie M. Relative contributions of diet and sunlight to vitamin D state in the elderly. Br Med J 2:303-305, 1979.
33. Baker MR, Peacock M, Nordin BE. The decline in vitamin D status with age. Age Ageing 9:249-252, 1980.
34. Matusoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 127:536-538, 1991.
35. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 121-126, 1996.
36. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 6:235-239, 1995.
37. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56:4108-4110, 1996.
38. Ingles SA, Ross RK, Yu MC, Irvine RA, Lapera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89:166-170, 1997.
39. Kibel AS, Isaacs SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 160:1405-1409, 1998.
40. 3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66:121-127, 1998.
41. Stevens A, Lowe JS. Male reproductive system. In: Stevens A, Lowe JS, Eds. Histology. London: Gower Medical Publishing, pp 304-321, 1992.
42. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810, 1994.
43. Konety BR, Schwartz GG, Acierno JS, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563-1570, 1996.
44. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92: 3439-3443, 1995.
45. Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer 60:395-399, 1995.
46. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ, Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50:5382-5386, 1990.
47. Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathol Res Pract 192:752-760, 1996.
48. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate 25:266-273, 1994.
49. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. The expression of waf-1, p53 and bcl-2 in prostate adenocarcinoma. Br J Urol 79:190-195, 1997.
50. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27:314-320, 1995.
51. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822, 1996.
52. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MN, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst 89:158-165, 1997.
53. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818, 1983.
54. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173:534-540, 1990.
55. 1. Endocrinology 138:1491-1497, 1997.
56. 3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 31:77-83, 1997.
57. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1α,25-Dihydroxyvitamin D (calcitrol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-732, 1997.
58. Water DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res 17:1467-1470, 1997.
59. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res 51:3814-3817, 1991.
60. Wang Y, Corr JC, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 84:1456-1462, 1995.
61. Lubaroff DM, Canfield L, Rasmussen GT, Reynolds CW. An animal model for the study of prostate carcinoma. Natl Cancer Inst Monogr 49:275-281, 1978.
62. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006, 1997.
63. Osborne JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195, 1995.
64. 3 (calcitriol). J Urol 159:2035-2040, 1998.
65. Holick MF, Krane SM, Potts JT Jr. Calcium, phosphorus, and bone metabolism: Calcium-regulating hormones. In: Fauci AS, Braunwald E, Isselbacher KJ, Martin JB, Eds. Principles of Internal Medicine (14th ed). New York: McGraw Hill, p. 2220, 1998.
66. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15-27, 1997.
67. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081, 1994.
68. 3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58:3370-3374, 1998.
69. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3:1331-1338, 1997.
70. 3 derivatives on growth, differentiation, and apoptosis in tumoral colonic HT29 cells: Possible implication of intracellular calcium. Cancer Lett 97:99-106, 1995.
71. 3 and prostate cancer cell proliferation in vivo. Urology 46:365-369, 1995.
72. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66: 413-425, 1997.
73. Hansen CM, Maenpaa PH. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 54:1173-1179, 1997.
74. 3. Endocrinology 136:20-26, 1995.
75. 3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Br J Urol 80:260-262, 1997.
76. Kissmeyer AM, Binderup E, Binderup L, Hansen M, Andersen NR, Makin HL, Schroeder NJ, Shankar VN, Jones G. Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 53: 1087-1097, 1997.
77. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectoral cancer. Br J Cancer 78:6-13, 1998.
78. Nemere I, Zhou LX, Norman AW. Nontranscriptional effects of steroid hormones. Receptor 3:277-291, 1993.
79. 3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem 269: 23750-23756, 1994.
80. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561, 1996.
81. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-288, 1996.
82. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90, 1997.
83. Zhao X, Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 132:1808-1814, 1993.
84. Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS, Lian JB. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: Dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 128:1496-1504, 1991.
85. 3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 119:2214-2220, 1986.
86. Suda T, Shinki T, Takahashi N. The role of vitamin D in bone and intestinal cell differentiation. Ann Rev Nutr 10:195-211, 1990.
87. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocrine Rev 13:66-80, 1992.
88. 3-induced monocytic differentiation of U937 cells. Leukemia Res 20:665-676, 1996.
89. 3. Proc Natl Acad Sci USA 78:4990-4994, 1981.
90. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, Valenzuela L, Murphy GP, Chu TM. Prostate antigen: A marker for human prostate epithelial cells. J Natl Cancer Inst 66:37-41, 1991.
91. Sinha AA, Wilson MJ, Gleason DF. Immunoelectron microscopic localization of prostatic-specific antigen in human prostate by the protein A-gold complex. Cancer 60:1288-1293, 1987.
92. Gleave ME, Hsieh JT, Wu H-C, Von Eschenbach AC, Chung LWK. Serum prostate-specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52:1598-1605, 1992.
93. Stamey TA, Kabalin JN. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 141:1070-1075, 1989.
94. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182-194, 1996.
95. 0 phase cell cycle block. Cell Prolif 27: 643-654, 1995.
96. 3 and EB 1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31-41, 1997.
97. 1 accumulation. Endocrinology 139:1197-1207, 1998.
98. Bartek J, Lukas J, Strauss M. A common path to tumor growth: Deregulation of Rb-dependent restriction point contol (review). Oncology Reports 3:237-240, 1996.
99. Sidle A, Palaty C, Dirks P, Wiggan O, Kiess M, Gill RM, Wong AK, Hamel PA. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol 31:237-271, 1996.
100. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262, 1998.
101. Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21:145-152, 1992.
102. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A 87:8751-8755, 1990.
103. 1 phase progression: Cycling on cue. Cell 79:551-555, 1994.
104. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153, 1996.
105. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 247:712-715, 1990.
106. 3. Int J Oncol 8:41-47, 1996.
107. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58:367-376, 1996.
108. 3-resistant variant. Endocrinology 138:4690-4698, 1997.
109. 3 protects HL60 cells against apoptosis but downregulates the expression of the bcl-2 gene. Exp Cell Res 209: 367-374, 1993.
110. 3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235:539-544, 1997.
111. 3 analog, EB1089. Endocrinology 139:2102-2110, 1998.
112. Chung LW. Implications of stromal-epithelial interaction in human prostate cancer growth, progression, and differentiation. Semin Cancer Biol 4:183-192, 1993.
113. Kooistra A, Konig JJ, Keizer DM, Romijn JC, Schroder FH. Inhibition of prostatic epithelial cell proliferation by a factor secreted specifically by prostatic stromal cells. Prostate 26:123-132, 1995.
114. Sandberg AA. Endocrine control and physiology of the prostate. Prostate 1:169-184, 1980.
115. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 12:287-301, 1993.
116. Peehl DM. Cellular biology of prostatic growth factors. Prostate (Suppl)6:74-78, 1996.
117. 3 and its analog EB1089. Int J Oncol 13:137-143, 1998.
118. 3. Prostate 26:72-79, 1995.
119. 3 regulation of transforming growth factor-β system in epithelial and fibroblastic cells: Relationships to plasminogen activation. J Invest Dermatol (Symp Proc) 1:33-38, 1996.
120. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor β on human prostate cancer cells in vitro Mol Cell Endocrinol 62:79-87, 1989.
121. Desruisseau S, Ghazarossian-Ragni E, Chinot O, Martin PM. Divergent effect of TGF1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Int J Cancer 66:796-801, 1996.
122. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404, 1991.
123. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM, Mulder E, Brinkmann AO. Cloning, structure, and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 153:241-248, 1988.
124. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 86:327-331, 1989.
125. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E. The human androgen receptor: Domain structure, genomic organization, and regulation of expression. J Steroid Biochem Mol Biol 34: 307-310, 1989.
126. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298, 1997.
127. 3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 223:141-146, 1996.
128. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71, 1992.
129. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Opthalmol Vis Sci 36:83, 1995.
130. 3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol (Symp Proc) 1:97-101, 1996.
131. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 Oncogene mutations in three human prostate cancer cell lines. Prostate 23:123-134, 1993.
132. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol 17:16-23, 1979.
133. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, Weichselbaum RR. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 46:31-36, 1991.
134. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274-281, 1978.
135. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR, Chiao JW. Establishment of a new human protatic cancer cell line. Invest Urol 36:79-84, 1990.
136. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003, 1995.
137. 3 on cellular proliferation, induction of 2′,5′-oligoadenylate (2-5A) synthetase and changes in immunoreactive pRB/p53 in human prostatic JCA-1 cells. Biochem Mol Biol Int 39:1085-1092, 1996.
138. Loop SM, Rozanski TA, Ostenson RC. Human primary prostate tumor cell line, ALVA-31: A new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 22:93-108, 1993.
139. Eaton CL, Pierrepoint CG. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: Isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate 12:129-143, 1988.
140. Castagnetta L, Carruba G, Granata OM, Lo Casto M, Arcuri F, Mesiti M, Pavone-Macaluso M. Prostate long-term epithelial cell lines: Biological and biochemical features. Ann N Y Acad Sci 595:64, 1990.
141. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54: 3413-3421, 1994.
142. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261-281, 1986.
143. Diamond DA, Barrack ER. The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J Urol 132:821-827, 1984.